Grizzly Bulls
Financial research concept

Life Sciences Tools Laboratory Products and Biopharma Services Organic Revenue Growth

measures acquisition- and currency-adjusted revenue growth in laboratory products and biopharma services.

By Lee BaileyPublished Oct 1, 2026
Research context

See what supports this page, how current it is, and where comparable or historical context is available.

Research date
Oct 1, 2026Use the dated article and cited sources for the definition, examples, and stated limitations.
Operating-model context
10 connected conceptsPart of the reviewed Life Sciences Tools & Biopharma Services Economics; issuer definitions remain distinct where disclosed.
Company examples
1 reviewed companyRelationships reflect supported examples, not a normalized cross-company KPI ranking.
  1. Organic growth sat below reported growth
  2. Acquisition-heavy reported growth needs a separate read
  3. Part of the Life Sciences Tools & Biopharma Services Economics
  4. See It in Company Research
  5. Continue Research

Life sciences tools Laboratory Products and Biopharma Services organic revenue growth measures segment revenue growth after excluding acquisition, divestiture, and currency effects under Thermo Fisher Scientific's methodology.

Thermo Fisher reported 5% organic revenue growth in the segment for the second quarter of 2026. Revenue was $6.693B, up from $5.995B a year earlier.

Organic growth sat below reported growth

Reported segment revenue increased 12%, including a 6% acquisition and divestiture effect and a 1% currency contribution.

Thermo Fisher said organic growth was primarily driven by the research and safety market channel and the clinical research business.

Acquisition-heavy reported growth needs a separate read

The Clario acquisition materially increased reported clinical research revenue, so reported sales growth alone overstates the period's underlying organic change.

Read organic growth with clinical research reported revenue growth contribution and segment income margin.

Primary source: Thermo Fisher Scientific Q2 2026 Form 10-Q.

Part of the Life Sciences Tools & Biopharma Services Economics

Connects Thermo Fisher's four operating segments through issuer-defined organic revenue growth, segment-income conversion, and disclosed business-level contributions to reported growth.

Browse the full operating model in Company Analysis →
Where this concept fits

See It in Company Research

These companies are examples of how the concept is reported or discussed in public filings. Definitions can differ by issuer; these links open company research rather than a normalized metric comparison.

Continue Research

Continue from the concept into the Grizzly Bulls research surface that best matches the next question. These links are research continuations, not recommendations or required steps.

Compare stocks

Compare lab products and biopharma organic growth

Compare underlying laboratory-products and biopharma-services growth after issuer-defined acquisition and currency adjustments.

Continue research

Explore more topics in the Financial Research Encyclopedia.